- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05140941
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (STORC)
April 4, 2024 updated by: Catherine Anne Chappell
Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus During Pregnancy (STORC)
This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy.
Treatment will be initiated during the second or third trimester in approximately 100 pregnant people.
Maternal participants will take one SOF/VEL tablet once daily for 12 weeks (84 days) and followed until 12 weeks after treatment completion (postpartum).
Infants will be followed from birth until one year of age.
The primary objectives are to evaluate the sustained virologic response 12 weeks after completion of SOF/VEL treatment (SVR12) in participants treated during pregnancy and to evaluate impact of antenatal treatment with SOF/VEL on the gestational age at delivery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase 4, multicenter study, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy.
Participants will be screened between 12+0 and 29+6 weeks of gestation confirmed by ultrasound.
HCV RNA level to confirm the patient has active infection will be obtained.
Laboratory evaluation of liver function will be obtained, to evaluate for renal insufficiency, decompensated cirrhosis and baseline elevations of lipase and creatine kinase.
Hepatitis B virus (HBV) antigen will be performed to look for evidence of active HBV infection.
Medical history and demographic information will also be collected at screening.
If the inclusion and exclusion criteria are met, the patient will be enrolled into the study between 20+0 and 30+0 weeks' gestation and initiate a 12-week course of a fixed-dose combination tablet of sofosbuvir 400 mg and velpatasvir 100 mg.
Maternal participants will take one SOF/VEL tablet once daily for 12 weeks (84 days).
The study will be completed in 8 or 9 visits (6 maternal visits and 3 infant visits).
The primary endpoints are 1) maternal HCV RNA PCR 12 weeks after completion of SOF/VEL treatment (HCV RNA PCR below the lower limit of quantification will be considered evidence of SVR12) and 2) preterm delivery (spontaneous and iatrogenic) prior to 37 weeks' gestation.
The secondary endpoints are 1) Maternal safety defined as maternal adverse events and pregnancy and delivery outcomes (stillbirth or intrauterine fetal demise, intrapartum hemorrhage, postpartum hemorrhage, hypertensive disorders of pregnancy, gestational diabetes, intrauterine growth restriction, cholestasis of pregnancy, severe maternal morbidity (defined by CDC), maternal admission to the intensive care unit, maternal death), 2) composite neonatal/Infant safety endpoints defined as severe neonatal morbidity with admission to neonatal intensive care unit and stratified by perinatal preterm (<37 weeks) (including fetal or neonatal death, severe bronchopulmonary dysplasia (grade 3) intraventricular hemorrhage grades III-IV, necrotizing enterocolitis (proven - Bell Stage 2A or greater), periventricular leukomalacia, retinopathy of prematurity stage III-V, or proven sepsis (early or late)) and perinatal term (>= 37 weeks) (including fetal or neonatal death, respiratory support , Apgar score ≤ 3 at 5 minutes, hypoxic ischemic encephalopathy, seizure, infection (sepsis or pneumonia), birth trauma, meconium aspiration syndrome, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support).
Other secondary endpoints are admission to the neonatal intensive care unit, neonatal death, major malformations, defined as structural abnormalities with medical, surgical or cosmetic importance, weight, length, and head circumference at birth (by exam or chart review), 8 weeks, six months and 12 months, neurodevelopmental assessments at 6 months and 12 months by Ages & Stages Questionnaires®, and infant HCV RNA PCR viral load at 8 weeks, 6 months and 12 months.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Catherine Chappell, MD, MSc
- Phone Number: 412-641-1403
- Email: chappellca@upmc.edu
Study Contact Backup
- Name: Leslie Meyn, PhD
- Phone Number: 412-641-4233
- Email: meynla@mwri.magee.edu
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- Victoria Hospital, London Health Sciences Center
-
Contact:
- Genevieve Eastabrook, MD
- Phone Number: 519-646-6106
- Email: genevieve.eastabrook@lhsc.on.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Recruiting
- Toronto General Hospital, University Health Network
-
Contact:
- Mia Biondi, PhD, NP-PHC
- Phone Number: 647-628-6461
- Email: mia.biondi@mail.mcgill.ca
-
Toronto, Ontario, Canada, M5B 1W8
- Recruiting
- University Health Toronto, St Michaels Hospital
-
Contact:
- Mark Yudin, MD
- Phone Number: 43075 416-864-6060
- Email: mark.yudin@unityhealth.to
-
-
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- The Christ Hospital
-
Contact:
- John Cafardi, MD
- Email: john.cafardi@thechristhospital.com
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University Wexner Medical Center
-
Contact:
- Kara Rood, MD
- Email: kara.rood@osumc.edu
-
Contact:
- Melanie L Paglione, MCR, BSN
- Phone Number: 614-685-5550
- Email: melanie.paglione@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh, Magee Womens Hospital
-
Contact:
- Catherine Chappell, MD
- Phone Number: 412-641-4242
- Email: chappellca@upmc.edu
-
Contact:
- Ingrid Macio
- Phone Number: 412-641-4242
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Recruiting
- University of Utah
-
Contact:
- Marcela Smid, MD
- Email: marcela.smid@hsc.utah.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 through 45 years (inclusive) at screening
- Able and willing to provide written informed consent and take part in the study procedures
- Able and willing to provide adequate locator information, defined as at least two other alternate contacts
- HCV antibody seropositivity with detectable HCV RNA viral load at screening
- Chronic HCV infection of at least 6 months by laboratory report or participant reported medical history as determined by the site PI, or if duration of HCV cannot be determined then the participant can be enrolled if there is no clinical evidence of acute hepatitis C infection (defined by CDC as presence of jaundice or total bilirubin >/= 3.0 mg/dL or ALT >200IU/L)
- Singleton pregnancy at 20 + 0 to 30 + 0 weeks' gestation at enrollment with gestational dating confirmed by ultrasound
- Having a comprehensive anatomy scan with no evidence of major structural abnormalities as defined by the CDC birth surveillance toolkit (https://www.cdc.gov/ncbddd/birthdefects/surveillancemanual/chapters/chapter-4/chapter4-1.html) or an anomaly that would significantly impact delivery timing or neonatal outcomes as determined by the Protocol Safety Review Team (PSRT) prior to enrollment
- Documented negative Hepatitis B testing for current infection (negative HBsAg test) prior to enrollment
- If living with HIV, must be on antiretroviral therapy with HIV viral load <50 copies/mL on the most recent HIV viral load test within 30 days before enrollment and agree to continue antiretroviral therapy throughout study participation
- If taking acid-suppressant medication(s), willing and able to either discontinue administration during the 12-week period of study treatment or to follow specific dosing instructions for concomitant use with SOF/VEL
- Per participant report at screening and enrollment, agrees not to participate in other research studies involving investigational medications or investigational medical devices for the duration of study participation (does not include duration of infant participation). Note: maternal participants can participate in research studies that include standard of care medications.
Exclusion Criteria:
Participant report of any of the following at screening or enrollment:
- Previous DAA treatment for HCV (prior interferon-based treatment is acceptable) without documentation of SVR12 (HCV RNA below the lower limit of quantification at least 24 weeks after DAA initiation)
- Use of any medications contraindicated with concurrent use of velpatasvir or sofosbuvir according to the most current EPCLUSA® package insert30
- Plans to relocate away from the study site area in the next 16 months and unable/unwilling to return for study visits
- History of cirrhosis documented or reported by previous liver biopsy, imaging tests or on at least 2 noninvasive laboratory tests of fibrosis, including compensated cirrhosis
- Reports participating in any other research study involving investigational medications or investigational medical devices within 60 days or less prior to enrollment (does not include research studies involving standard of care medications)
- Known fetal chromosomal abnormality prior to enrollment (confirmed by chorionic villus sampling or amniocentesis)
- Clinically significant and habitual non-therapeutic drug use, not including marijuana, as determined by site PI at screening and enrollment
- At screening and enrollment, as determined by site PI, any significant, uncontrolled, active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease other than HCV (or HIV as outlined in eligibility criteria)
Any of the following laboratory abnormalities at screening:
- Aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 10 times the upper limit of normal
- Hemoglobin less than 9 g/dL
- Platelet count less than 90,000 per mm3
- International normalized ratio (INR) > 1.5
- Creatinine greater than 1.4
- If living with HIV, CD4 count less than 200 cells/mm3 within 6 months of enrollment.
- Any other condition that, in the opinion of the site PI/designee, would preclude appropriate informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sofosbuvir/Velpatasvir
Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, one tablet taken once daily for 84 days
|
One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of maternal participants with sustained virologic response after completion of SOF/VEL treatment (SVR12)
Time Frame: Approximately 12 weeks
|
Number of maternal participants with plasma level of HCV RNA PCR that is below the lower limit of quantification after completion of SOF/VEL treatment
|
Approximately 12 weeks
|
Number of maternal participants that deliver prior to 37 weeks' gestation
Time Frame: Approximately 28 weeks
|
Number of maternal participants that deliver (spontaneous and iatrogenic) prior to 37 weeks' gestation
|
Approximately 28 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of maternal participants that experience an adverse event that is deemed related to Sofosbuvir/Velpatasvir
Time Frame: Approximately six months
|
Number of maternal participants that experience an adverse event that is deemed related to Sofosbuvir/Velpatasvir by a study physician
|
Approximately six months
|
Number of infants that experience an adverse event that is deemed related to Sofosbuvir/Velpatasvir
Time Frame: Approximately six months
|
Number of infant participants that experience an adverse event that is deemed related to Sofosbuvir/Velpatasvir by a study physician
|
Approximately six months
|
Number of maternal participants whose pregnancy results in a stillbirth or intrauterine fetal demise
Time Frame: Approximately 28 weeks
|
Number of maternal participants whose pregnancy results in a stillbirth or intrauterine fetal demise
|
Approximately 28 weeks
|
Number of maternal participants that experience intrapartum hemorrhage
Time Frame: Approximately 28 weeks
|
Number of maternal participants that experience intrapartum hemorrhage
|
Approximately 28 weeks
|
Number of maternal participants that experience postpartum hemorrhage
Time Frame: Approximately 28 weeks
|
Number of maternal participants that experience postpartum hemorrhage
|
Approximately 28 weeks
|
Number of maternal participants that experience a hypertensive disorder of pregnancy
Time Frame: Approximately 28 weeks
|
Number of maternal participants that experience a hypertensive disorder of pregnancy (gestational hypertension, pre-eclampsia with and without severe features, eclampsia)
|
Approximately 28 weeks
|
Number of maternal participants that develop gestational diabetes
Time Frame: Approximately 28 weeks
|
Number of maternal participants that develop gestational diabetes
|
Approximately 28 weeks
|
Number of maternal participants that experience cholestasis of pregnancy
Time Frame: Approximately 28 weeks
|
Number of maternal participants that experience cholestasis of pregnancy
|
Approximately 28 weeks
|
Number of maternal participants that experience intrauterine growth restriction
Time Frame: Approximately 28 weeks
|
Number of maternal participants that experience intrauterine growth restriction
|
Approximately 28 weeks
|
Number of maternal participants that develop severe maternal morbidity
Time Frame: Approximately 28 weeks
|
Number of maternal participants that develop severe maternal morbidity, as defined by the Centers for Disease Control
|
Approximately 28 weeks
|
Number of maternal participants that are admitted to the intensive care unit
Time Frame: Approximately 28 weeks
|
Number of maternal participants that are admitted to the intensive care unit
|
Approximately 28 weeks
|
Number of maternal deaths
Time Frame: Approximately 28 weeks
|
Number of maternal deaths
|
Approximately 28 weeks
|
Number of preterm neonates (<37 weeks) admitted to the neonatal intensive care unit for severe neonatal morbidity
Time Frame: Approximately 4 weeks
|
Perinatal preterm (<37 weeks) composite outcome defined as fetal or neonatal death, or admission to the neonatal intensive care unit for severe bronchopulmonary dysplasia (grade 3), intraventricular hemorrhage grades III-IV, necrotizing enterocolitis (proven - Bell Stage 2A or greater), periventricular leukomalacia, retinopathy of prematurity stage III-V, or proven sepsis (early or late)
|
Approximately 4 weeks
|
Number of term neonates (>=37 weeks) admitted to the neonatal intensive care unit for severe neonatal morbidity
Time Frame: Approximately 4 weeks
|
Perinatal term (<37 weeks) composite outcome defined as fetal or neonatal death, or admission to the neonatal intensive care unit for respiratory support, Apgar score ≤ 3 at 5 minutes, hypoxic ischemic encephalopathy, seizure, infection (sepsis or pneumonia), birth trauma, meconium aspiration syndrome, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support
|
Approximately 4 weeks
|
Number of neonates admitted to the neonatal intensive care unit
Time Frame: Approximately 4 weeks
|
Number of neonates admitted to the neonatal intensive care unit
|
Approximately 4 weeks
|
Number of neonatal deaths
Time Frame: Approximately 4 weeks
|
Number of neonatal deaths
|
Approximately 4 weeks
|
Number of neonates with major malformations
Time Frame: Approximately 4 weeks
|
Number of neonates with major malformations, defined as structural abnormalities with medical, surgical or cosmetic importance.
|
Approximately 4 weeks
|
Weight of infant participant at 8 Weeks
Time Frame: Approximately 8 weeks
|
Weight of infant participant measured at 8 weeks (by exam or chart review)
|
Approximately 8 weeks
|
Weight of infant participant at 6 months
Time Frame: Approximately 6 months
|
Weight of infant participant measured at 6 months (by exam or chart review)
|
Approximately 6 months
|
Weight of infant participant at 12 months
Time Frame: Approximately 12 months
|
Weight of infant participant measured at 12 months (by exam or chart review)
|
Approximately 12 months
|
Length of infant participant at 8 weeks
Time Frame: Approximately 8 weeks
|
Length of infant participant measured at 8 weeks (by exam or chart review)
|
Approximately 8 weeks
|
Length of infant participant at 6 months
Time Frame: Approximately 6 months
|
Length of infant participant measured at 6 months (by exam or chart review)
|
Approximately 6 months
|
Length of infant participant at 12 months
Time Frame: Approximately 12 months
|
Length of infant participant measured at 12 months (by exam or chart review)
|
Approximately 12 months
|
Head circumference of infant participant at 8 weeks
Time Frame: Approximately 8 weeks
|
Head circumference of infant participant measured at 8 weeks (by exam or chart review)
|
Approximately 8 weeks
|
Head circumference of infant participant at 6 months
Time Frame: Approximately 6 months
|
Head circumference of infant participant measured at 6 months (by exam or chart review)
|
Approximately 6 months
|
Head circumference of infant participant at 12 months
Time Frame: Approximately 12 months
|
Head circumference of infant participant measured at 12 months (by exam or chart review)
|
Approximately 12 months
|
Number of Infant Participants with Any Neurological Development Score Less than 6 at 6 months
Time Frame: Approximately 6 months
|
Number of infant participants with a Bayley's score of less than 6 on either cognitive, motor or language development assessments evaluated at 6 months; Bayley's score ranges from 1 (extremely low) to 19 (very superior)
|
Approximately 6 months
|
Number of Infant Participants with Any Neurological Development Score Less than 6 at 12 months
Time Frame: Approximately 12 months
|
Number of infant participants with a Bayley's score of less than 6 on either cognitive, motor or language development assessments evaluated at 12 months; Bayley's score ranges from 1 (extremely low) to 19 (very superior)
|
Approximately 12 months
|
Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 8 weeks
Time Frame: Approximately 8 weeks
|
Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 8 weeks
|
Approximately 8 weeks
|
Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 6 months
Time Frame: Approximately 6 months
|
Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 6 months
|
Approximately 6 months
|
Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 12 months
Time Frame: Approximately 12 months
|
Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 12 months
|
Approximately 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Catherine Chappell, MD, MSc, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 4, 2022
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
November 5, 2021
First Submitted That Met QC Criteria
November 18, 2021
First Posted (Actual)
December 2, 2021
Study Record Updates
Last Update Posted (Actual)
April 8, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Pregnancy Complications
- Chronic Disease
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Pregnancy Complications, Infectious
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
- Sofosbuvir-velpatasvir drug combination
- Velpatasvir
Other Study ID Numbers
- STUDY21080043
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The protocol will be published with the primary manuscript.
Other data inquires can be made by e-mailing the PI at the address below after the primary manuscript has been published for 5 years time.
IPD Sharing Time Frame
Immediately after the primary manuscript for the study is published for five years.
IPD Sharing Access Criteria
Data requests submitted by email will be reviewed by the Principal Investigator.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C, Chronic
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
-
Kirby InstituteRecruitingHepatitis C | Liver Cirrhoses | Liver InflammationAustralia
-
Ohio State UniversityCompletedHepatitis C | HCV | Kidney TransplantUnited States
-
Queen Mary University of LondonUniversity of Oxford; Aga Khan University; University of Bristol; Dow University...Enrolling by invitation
-
Instituto Nacional de Ciencias Medicas y Nutricion...Gilead SciencesNot yet recruitingHepatitis C in Substance Users
-
Hannover Medical SchoolGilead Sciences; HepNet Study House, German Liverfoundation; German Center for...CompletedHepatitis C | Acute Hepatitis CGermany
-
National Taiwan University HospitalRecruitingHepatitis C Virus Infection | Treatment Side Effects | Effect of Drug | Adherence, TreatmentTaiwan
-
University Health Network, TorontoGilead SciencesActive, not recruiting
-
Ilkos Therapeutic Inc.CompletedVenous Leg UlcerSpain, Hungary, Canada, United States, Brazil, Argentina, Austria, Czechia, Italy, Poland, Slovakia
-
University of Maryland, BaltimoreGilead SciencesCompleted
-
University of DundeeCompletedHepatitis CUnited Kingdom